Obinutuzumab Wins FDA Approval for Membranous Nephropathy

FDA approved obinutuzumab for membranous nephropathy after a trial showed markedly higher complete proteinuria remission than tacrolimus at 104 weeks. Better long-term kidney-function preservation has not been established; boxed warnings and serious adverse events warrant careful benefit-risk assessment.